As its CEO Jerome Carle steps down following a 67% slump in sales to date this year, UAE-based Julphar is hopeful of putting manufacturing problems behind it under a new management team.

Krka has revealed its new growth strategy for 2020-2024, including growing through joint ventures, partnerships and acquisitions and focusing on European, central Asian and Chinese markets. At the same time, the Slovenian firm has reported that its sales jumped by 12% in the first nine months of 2019.

US niche generics player Teligent intends to use its expertise in topical and injectable drugs manufacturing to push into the North American ophthalmics sector.

Piramal says it is looking to build on the 17% growth in its Global Pharma business reported in its financial second quarter by investing in manufacturing expansion across differentiated product areas.

India’s Ajanta has reported a 7% drop in second-quarter net profit with its African branded generics remaining a problem area. However, US sales climbed by nearly 40% and analysts remain positive on the company’s outlook, buoyed by a beat on revenue estimates.

By the middle of next year, Emcure intends to have demerged its operations in highly developed markets from its activities in India and other emerging markets. The Indian group is seeking private-equity support to grow inorganically in North America and Europe.